Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Neoplasms 2Leukemia, Myeloid 2Bronchiolitis Obliterans Syndrome 1

Interventions

Cytarabine 899Cyclophosphamide 894fludarabine 517venetoclax 475fludarabine phosphate 464Azacitidine 452Rituximab 418Methotrexate 415Etoposide 319Filgrastim 299Busulfan 295Dexamethasone 285Vincristine 281Daunorubicin 280Peripheral Blood Stem Cell Transplantation 257Whole-Body Irradiation 240Mycophenolic Acid 231Decitabine 228Granulocyte Colony-Stimulating Factor 225Tacrolimus 219Idarubicin 203Melphalan 201Imatinib Mesylate 195Cyclosporine 182Doxorubicin 177Radiotherapy 169Prednisone 161Mitoxantrone 160Lenalidomide 159Mercaptopurine 155

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × RO6839921 × Other hematologic neoplasm × Clear all
NCT02098967 2018-05-17

A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.

Hoffmann-La Roche

Phase 1 Completed
68 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Neoplasms

NCT01677780 2017-07-07

An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies

Hoffmann-La Roche

Phase 1 Completed
11 enrolled
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myeloid, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡